Drug price adjustment ideas: "lower and higher"

Song Dacai, director of the Price Division of the Department of Price of the National Development and Reform Commission, revealed at the meeting of representatives of the “Sound and Responsibility” two-party medical and health circles that the list of low-priced drugs is expected to be introduced in the first half of the year. In the future, the price of hemp drugs will continue to adjust. The price adjustment of Chinese medicines is in preparation for the first time, and he will strive to land within the year.

At the end of last year, at the symposium on pharmaceutical prices held by the National Development and Reform Commission, the Price Division of the National Development and Reform Commission once again discussed low-priced drugs for which opinions were solicited. In 2014, the idea of ​​“lower, higher, and higher” drug price management was clear .

Chinese patent medicine price suspense

In January 2013, the National Development and Reform Commission issued the 31st round of drug price adjustment plan, and the entire category of medical list price reduction plan was settled. However, the price adjustment of proprietary Chinese medicines in the medical insurance list has not yet been introduced. In 2013, the price adjustment plan of Chinese patent medicine was expected. Has also failed.

According to the reporter’s understanding, the price adjustment plan for Chinese patent medicines has been put on the agenda of the Development and Reform Commission in 2012. As early as September 2012, the National Development and Reform Commission had already carried out cost-finding work on proprietary Chinese medicines; after entering into October, it held two seminars on the price assessment of Chinese patent medicines to prepare for price adjustment.

Since 2013, the NDRC successively organized internal meetings on several occasions to discuss the price adjustment plan. The market's most concerned price adjustments for proprietary Chinese medicines are different, with the most controversial drops in the prices of exclusive varieties and Chinese medicine injections.

Each has its own arrangements

Previously, the industry ransacked that the NDRC hopes to shift the drug price management model from the "highest retail price" to the "base price", and some high-priced drugs will face the adjustment of the highest retail price. In this case, Song Dacai stated at the forum that the benchmark price must be submitted to the State Council for examination and approval before it can be pushed open. Now, no trial has yet begun.

In the first half of last year, the Price Division of the National Development and Reform Commission conducted a round of solicitation of opinions, but the work has been slow. Song Dacai also said that the current conditions for full implementation are not yet mature, and plans to carry out pilot projects by selecting some localities.

At the end of last year, the National Development and Reform Commission issued the "Notice on improving the management of low-cost medicines (Draft for Soliciting Opinions)". 890 types of dosage forms were included in the list of low-priced medicines. The average daily cost of chemical medicines is expected to be less than 3 yuan and Chinese medicine 5 The products below RMB are included in the list of low-priced drugs, and the highest retail price of the products in the catalogue is cancelled, which is changed by the enterprises’ independent pricing and the Provincial Price Bureau.

“The core idea of ​​this reform policy is to formulate a reasonable daily use cost standard, delineate corresponding standards according to different categories of Chinese medicines and chemical drugs, and eliminate the price limit of retail price of drugs that are included in the scope of low-priced drugs. The manufacturer will independently determine the cost standard. Price.” Song Dacai said.

Compared with low-priced drugs, the adjustment of drug prices for high-priced drugs is also a concern. Last year, the Health and Family Planning Commission made it clear that it would establish a price negotiation mechanism to negotiate with the top 200 companies, such as joint ventures and imported drugs, to reduce the inflated prices of these drugs nationwide. The Development and Reform Commission also made it clear that the highest retail price of high-priced drugs should also be adjusted. This shows that with the introduction of the latest version of the medical insurance list, the adjustment of high-priced drugs will usher in a wave of climax.